Invivyd IVVD 深 滬
等待開盤 09-17 09:30:00 美东时间
0.8053
-0.025
-2.98%
華盛通- 最 高0.84
- 今 開0.83
- 成交量 359.40万股
- 最 低 0.8007
- 昨 收 0.83
- 總市值 2.37亿
- 52周最高 3.0699
- 市盈率 靜 --
- 換手率 1.22%
- 52周最低 0.5277
- 委 比 1.48%
- 總股本 2.95亿
- 歷史最高 78.82
- 量 比 1.11
- 振 幅 4.73%
- 歷史最低 0.3546
- 每 手 1
- 風險率 0.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 机构看淡消费股！麦当劳、耐克、卡夫亨氏齐遭降目标价；能源股获齐声唱多
今日重点评级关注：Ascendiant Capital：维持SurgePays"买入"评级，目标价从3.5美元升至3.75美元；HC Wainwright & Co.：维持Spero Therapeutics"买入"评级，目标价从5美元升至6美元
09-15 15:30
BTIG Reiterates Buy on Invivyd, Maintains $10 Price Target
BTIG analyst Thomas Shrader reiterates Invivyd (NASDAQ:IVVD) with a Buy and maintains $10 price target.
09-14 20:24
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd, Inc. granted 255,000 stock options to six new non-executive employees on September 1, 2026, under its 2026 Inducement Plan. The options, exercisable at $0.8799 per share, vest over four years and have a 10-year term. Invivyd, a biopharmaceutical company focused on viral infectious diseases, aims to develop best-in-class antibodies.
09-03 11:01
Invivyd Continues To Expect Top-Line Data From VYD2311 Program Around The End Of Q3 2026
Invivyd continues to expect top-line data from the VYD2311 program around the end of Q3 2026. At that time, Invivyd plans to either unblind the DECLARATION study in its entirety and submit a Biologics License Application (BLA) towards traditional product approval, or partially unblind the study (lea...
09-01 19:10
Invivyd Appoints Marc Elia As CEO
Mr. Elia has served as Chairman of Invivyd’s Board of Directors since June of 2022; has architected Invivyd’s scientific and corporate strategy Ajay Royan, Founder of Mithril Capital and a founding, long-term investor in Invivyd, appointed Lead Independent Director Ian Sheffield appointed to Invivyd...
09-01 19:08
美股大行评级 | 潜在涨幅1024.26%！Ascendiant Capital上调PAVmed目标价至57美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从56美元升至57美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9.25美元升至9.5美元
08-28 16:15
Cantor Fitzgerald Reiterates Overweight on Invivyd, Maintains $10 Price Target
Cantor Fitzgerald analyst Josh Schimmer reiterates Invivyd (NASDAQ:IVVD) with a Overweight and maintains $10 price target.
08-27 19:14
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Invivyd, Inc. granted stock options to 10 new employees totaling 277,500 shares, priced at $0.535 per share, vesting over four years. The options, granted under the 2026 Inducement Plan, have a 10-year term. Invivyd is a biopharmaceutical company focused on developing antibodies against serious viral diseases, including SARS-CoV-2, with a proprietary technology platform.
08-04 11:01
美股牛股 | 制药企业CRNX股价狂飙近99%！获福泰制药百亿美元高溢价收购；罕见病药物研究公司AGIO涨18%
制药企业CRNX股价狂飙近99%！获福泰制药百亿美元高溢价收购；罕见病药物研究公司AGIO涨18%，核心产品新药申请获FDA受理；基因治疗药物研发企业NGNE涨13%，公司成功完成新一轮融资>>
07-08 19:19
Invivyd gets notice of Pemgarda EUA termination
Invivyd (IVVD) received a notice from the U.S. Food and Drug Administration terminating the emergency use authorization for PEMGARDA, its monoclonal antibody for COVID-19 prevention, effective June 29...
07-06 19:36
